

## ADMET Prediction of the Dominant Compound from Mangosteen (*Garcinia mangostana* L.) using pkCSM: A Computational Approach

Faisal Akhmal Muslikh<sup>1\*</sup>, Evi Kurniawati<sup>2</sup>, Burhan Ma'arif<sup>3</sup>, Syendriva Zeptyan Zenmas<sup>4</sup>, Novyananda Salmasfattah<sup>5</sup>, Anis Akhwan Dhafin<sup>6</sup>, Fendy Prasetyawan<sup>7</sup>

<sup>1,2,4</sup> Institut Ilmu Kesehatan Bhakti Wiyata, <sup>3</sup> Universitas Islam Negeri Maulana Malik Ibrahim, <sup>5</sup> Institut Teknologi Sains dan Kesehatan RS.DR. Soepraoen Kesdam V/BRW <sup>6,7</sup> Universitas Kadiri

**Corresponding Author:** Faisal Akhmal Muslikh; [faisal.akhmal@iik.ac.id](mailto:faisal.akhmal@iik.ac.id)

---

### ARTICLE INFO

**Keywords:**  $\alpha$ -mangostin; ADMET Prediction; *Garcinia mangostana* L.; pkCSM

*Received :* 2 December

*Revised :* 16 December

*Accepted:* 29 December

©2023Muslikh, Kurniawati, Ma'arif, Zenmas, Salmasfattah, Dhafin, Prasetyawan: This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/).



---

### ABSTRACT

Mangosteen (*Garcinia mangostana* L.) is a plant belonging to the Guttiferae family with origins in Southeast Asia. The primary components in mangosteen peel consist of xanthenes, particularly  $\alpha$ -mangostin, which displays diverse pharmacological effects such as anti-diabetic properties, antioxidant activity, and anti-inflammatory effects. However, due to the insufficient information regarding studies on pharmacokinetics (administration, distribution, metabolism, excretion, and toxicity), the objective of this investigation is to explore pharmacokinetic predictions utilizing the pkCSM web tool. The  $\alpha$ -mangostin compound, acquired from PubChem accessible at <https://pubchem.ncbi.nlm.nih.gov/>, underwent pharmacokinetic analysis using the web tool available at <https://biosig.lab.uq.edu.au/pkcsm/prediction>. The study findings revealed that the  $\alpha$ -mangostin compound, subjected to pharmacokinetic analysis with pkCSM, exhibited limited distribution capability

---

## INTRODUCTION

Mangosteen (*Garcinia mangostana* L.) is a plant that originates from the Guttiferae family and has its roots in Southeast Asia, often cultivated extensively for harvesting purposes (Theapparatt et al., 2019). Mangosteen trees can reach heights of 6-25 meters, featuring dense leaves and a rough canopy, with a trunk diameter ranging from 25 to 35 cm, and a bark that varies from brown to black. The tree's structure includes asymmetrical branches that aid in forming a pyramidal crown (Priyanti et al., 2022). Mangosteen fruit has a dark purple or reddish color, containing soft and juicy white pulp that is edible, and it has a slightly acidic taste (Ibrahim et al., 2014). Mangosteen is renowned as the "Foods of God" due to its unique and distinctive flavor (Ibrahim et al., 2015; Priyanti et al., 2022).

The use of plants as traditional medicine, including *G. mangostana*, is related to the content of secondary metabolites and their biological activities. For example, the presence of phenolic compounds is often associated with biological activity as antioxidants (Ngawhirunpat et al., 2010). In recent years, the use of *G. mangostana* as a component of traditional medicine has been growing and is believed to have the potential to treat various diseases such as cancer, diabetes mellitus, and heart issues (Silalahi, 2021).

## LITERATURE REVIEW

The primary constituents found in mangosteen's pericarp include xanthenes, specifically  $\alpha$ -mangostin,  $\beta$ -mangostin,  $\gamma$ -mangostin, garcinone E, 8-deoxygartanin, totophyllin A and B, mangostanol, mangostenin, and mangostenones C, D, and E. The key xanthone derivative,  $\alpha$ -mangostin, exhibits various pharmacological effects such as antidiabetic properties, antioxidant activity, and anti-inflammatory effects (Husen et al., 2017; Ansori et al., 2020), in the mangosteen pericarp part there is 121.01 mg/g, while in the mangosteen leaf part there is around 2.10% (Ghasemzadeh et al., 2018; Rahmiyani et al., 2023). Due to a lack of information regarding studies on pharmacokinetics (administration, distribution, metabolism, excretion, and toxicity), the objective of this research is to discuss pharmacokinetic predictions using the web tool pkCSM.

## METHODOLOGY

The compound  $\alpha$ -mangostin was obtained from the chemical compound library portal of PubChem (<https://pubchem.ncbi.nlm.nih.gov/>). The comprehensive chemical compound data, which includes Simplified Molecular-Input Line-Entry System (SMILES) data, was retrieved (Jamil and Saputro, 2023). Subsequently, physicochemical and pharmacokinetic analyses were performed using the pkCSM web tool (<https://biosig.lab.uq.edu.au/pkcsml/prediction>) by inputting the SMILES code for each compound. After entering the SMILES code, users can choose the "ADMET" option on the pkCSM platform and patiently wait for the analysis process to complete. This method provides valuable insights into the absorption, distribution, metabolism, excretion, and toxicity (ADMET)

properties of the mentioned compounds (Muslikh et al., 2023a; Muslikh et al., 2023b).

## RESEARCH RESULT AND DISCUSSION

The results of the pharmacokinetic test indicate that  $\alpha$ -mangostin exhibits good absorption characteristics based on absorption criteria in the human intestine, but it has less permeability through CaCO<sub>2</sub> and high permeability through the skin, as detailed in Table 1. Additionally, concerning distribution parameters, the compound  $\alpha$ -mangostin has limited distribution ability, as it only has a CNS permeability value of -1.984, suggesting its potential as a promising drug candidate for targeting the central nervous system (CNS) (Gondokesumo et al., 2024).

Table 1. Prediction of  $\alpha$ -mangostin Pharmacokinetics

| Parameter                                                          | $\alpha$ -mangostin | Indicators                                                  |
|--------------------------------------------------------------------|---------------------|-------------------------------------------------------------|
| <b>Absorption</b>                                                  |                     |                                                             |
| CaCO <sub>2</sub> permeability (log Papp in 10 <sup>-6</sup> cm/s) | -0.048              | High CaCO <sub>2</sub> permeability would value >0.90       |
| Intestinal absorption (human) (% Absorbed)                         | 93.647              | Poor absorption, < 30%                                      |
| Skin permeability (log Kp)                                         | -2.736              | Low, log Kp > -2.5                                          |
| <b>Distribution</b>                                                |                     |                                                             |
| VDSS (human) (log L/kg)                                            | -0.282              | Low, log < -0.15<br>High, log > 0.45                        |
| BBB permeability (log BB)                                          | -1.075              | Good, logBB > 0.3<br>Poor, logBB < -1                       |
| CNS permeability (log PS)                                          | -1.984              | Can penetrate, Log PS > -2<br>Cannot penetrate, Log PS < -3 |
| <b>Metabolism</b>                                                  |                     |                                                             |
| CYP2D6 Substrates                                                  | No                  | Yes/No                                                      |
| CYP3A4 Substrates                                                  | Yes                 | Yes/No                                                      |
| CYP1A2 inhibitors                                                  | Yes                 | Yes/No                                                      |
| CYP2C19 inhibitors                                                 | Yes                 | Yes/No                                                      |
| CYP2C9 inhibitors                                                  | Yes                 | Yes/No                                                      |
| CYP2D6 inhibitors                                                  | No                  | Yes/No                                                      |
| CYP3A4 inhibitors                                                  | No                  | Yes/No                                                      |
| <b>Excretion</b>                                                   |                     |                                                             |
| Total clearances                                                   | 0.43                | Higher is better                                            |
| Renal OCT2 substrates                                              | No                  | Yes/No                                                      |
| <b>Toxicity</b>                                                    |                     |                                                             |
| AMES toxicity                                                      | Yes                 | Yes/No                                                      |
| Max. tolerated dose (human) (log mg/kg/day)                        | 0.061               | -                                                           |
| hERG I inhibitors                                                  | No                  | Yes/No                                                      |
| hERG II inhibitors                                                 | Yes                 | Yes/No                                                      |
| Hepatotoxicity                                                     | No                  | Yes/No                                                      |
| Skin Sensitization                                                 | No                  | Yes/No                                                      |
| <i>T. Pyriformis</i> toxicity (log ug/L)                           | 0.325               | Toxic, Log > 0.5 ug/L                                       |
| Minnow toxicity (log mM)                                           | -0.138              | The acute toxicity is high, Log < - 0.3                     |

Regarding metabolic parameters, the evaluation of cytochrome P450 inhibition and metabolic indicator produced diverse results.  $\alpha$ -Mangostin was identified as a potential substrate for CYP3A4 and showed inhibitory effects on CYP1A2, CYP2C19, and CYP2C9 inhibitors.

In the process of designing drug candidates, toxicity assessment is a crucial parameter. Findings from the toxicity test reveal that  $\alpha$ -mangostin exhibits toxicity towards AMES and hERG II inhibitors (Pires et al., 2015; Ma'arif et al., 2021; Muslikh et al., 2022). In the context of excretion analysis, it is noteworthy that  $\alpha$ -mangostin shows higher total clearance values. Furthermore,  $\alpha$ -mangostin is not categorized as a substrate for renal OCT2, indicating a lack of toxic effects in oral formulations, especially when administered concurrently with a renal OCT2 inhibitor (Pires et al., 2015).

## CONCLUSIONS AND RECOMMENDATIONS

The primary compound discovered in Mangosteen (*Garcinia mangostana* L.) is  $\alpha$ -mangostin. An in silico pharmacokinetic analysis using the pkCSM suggests that this compound exhibits limited distribution capabilities. Additional studies can be undertaken to formulate drugs utilizing  $\alpha$ -mangostin, aiming to improve its distribution characteristics.

## REFERENCES

- Ansori, A. N. M., Fadholly, A., Hayaza, S., Susilo, R. J. K., Inayatillah, B., Winarni, D., & Husen, S. A. (2020). A review on medicinal properties of mangosteen (*Garcinia mangostana* L.). *Research Journal of Pharmacy and Technology*, 13(2), 974-982. <https://doi.org/10.5958/0974-360X.2020.00182.1>
- Ghasemzadeh, A., Jaafar, H. Z., Baghdadi, A., & Tayebi-Meigooni, A. (2018). Alpha-mangostin-rich extracts from mangosteen pericarp: optimization of green extraction protocol and evaluation of biological activity. *Molecules*, 23(8), 1852. <https://doi.org/10.3390/molecules23081852>
- Gondokesumo, M. E., Muslikh, F. A., Pratama, R. R., Ma'arif, B., et al. (2024). The potential of 12 flavonoid compounds as alzheimer's inhibitors through an in silico approach. *Journal of Medicinal and Pharmaceutical Chemistry Research*. 6(1): 50-61. <https://doi.org/10.48309/jmpcr.2024.182761>
- Husen, S. A., Khaleyla, F., Ansori, A. N. M., Susilo, R. J. K., & Winarni, D. (2017). Antioxidant activity assay of alpha-mangostin for amelioration of kidney structure and function in diabetic mice. In 1st International Conference Postgraduate School Universitas Airlangga: "Implementation of Climate Change Agreement to Meet Sustainable Development Goals"(ICPSUAS 2017) (pp. 84-88). Atlantis Press.
- Ibrahim, U. K., Austin, E. A., & Mohd Salleh, R. (2015). Effect of Drying Temperature and Time on Antioxidant and Total Phenolic Content in *Garcinia mangostana* Pericarp. *Advanced Materials Research*, 1113, 279-284. <https://doi.org/10.4028/www.scientific.net/AMR.1113.279>
- Ibrahim, M. Y., Hashim, N. M., Mariod, A. A., Mohan, S., Abdulla, M. A., Abdelwahab, S. I., & Arbab, I. A. (2016).  $\alpha$ -Mangostin from *Garcinia mangostana* Linn: an updated review of its pharmacological properties. *Arabian journal of Chemistry*, 9(3), 317-329. <https://doi.org/10.1016/j.arabjc.2014.02.011>
- Jamil, A. S., & Saputro, P. G. (2023). Molecular Docking and ADME Studies of *Centella Asiatica* as Anti Hyperuricemia. *Pharmacognosy Journal*, 15 (2).
- Ma'arif, B., Aminullah, M., Saidah, N. L., Muslikh, F. A., Rahmawati, A., Indrawijaya, Y. Y. A., ... & Taek, M. M. (2021). Prediction of antiosteoporosis activity of thirty-nine phytoestrogen compounds in estrogen receptor-dependent manner through in silico approach. *Tropical Journal of Natural Product Research*, 5(10), 1727-1734.

- Muslikh, F. A., Samudra, R. R., Ma'arif, B., Ulhaq, Z. S., Hardjono, S., & Agil, M. (2022). In Silico Molecular Docking and ADMET Analysis for Drug Development of Phytoestrogens Compound with Its Evaluation of Neurodegenerative Diseases. *Borneo Journal of Pharmacy*, 5(4), 357-366. <https://doi.org/10.33084/bjop.v5i4.3801>
- Muslikh, F. A., Prasetyawan, F., Hesturini, R. J., Sari, F., ....., Mawarni, O. K. (2023a). Physicochemical and Pharmacokinetic Property Prediction of Substances in Centella asiatica using pkCSM: Prospects for the Creation of Therapeutic Formulations from Plant Isolates. *International Journal of Global Sustainable Research*, 1 (3), 485-494. <https://doi.org/10.59890/ijgsr.v1i3.892>
- Muslikh, F. A., Dhafin, A. A., & Prasetyawan, F. (2023b). Prediction of Pinostrobin Pharmacokinetics from Temu Kunci (*Boesenbergia rotunda* (L.) Mansf.) Using pkCSM. *Contemporary Journal of Applied Sciences*, 1(1), 1-6. <https://doi.org/10.55927/cjas.v1i1.6977>
- Ngawhirunpat, T., Opanasopi, P., Sukma, M., Sittisombut, C., Kat, A., & Adachi, I. (2010). Antioxidant, free radical-scavenging activity and cytotoxicity of different solvent extracts and their phenolic constituents from the fruit hull of mangosteen (*Garcinia mangostana*). *Pharmaceutical Biology*, 48(1), 55-62. <https://doi.org/10.3109/13880200903046138>
- Prajayanti, N. K. D., Arlen, V., Namba, G. A. S., Basule, V., Wea, F. E. V., Utomo, L. S., & Djunarko, I. (2022). Manfaat Manggis (*Garcinia mangostana*) Sebagai Antioksidan. *JCPS (Journal of Current Pharmaceutical Sciences)*, 6(1), 540-549.
- Rahmiyani, I., Yuliana, A., Rukmana, D. H., Tuslinah, L., & Nurviana, V. (2023).  $\alpha$ -Mangostin Content of Mangosteen Leaves (*Garcinia mangostana* L.) Based on Different Growing Conditions. *PLANTA TROPICA*, 11(2), 125-132. <https://doi.org/10.18196/pt.v11i2.16848>
- Silalahi, M. (2021). Manfaat dan Bioaktivitas dari Manggis (*Garcinia mangostana* L.). *BIOEDUKASI (Jurnal Pendidikan Biologi)*, 12(1), 30-37. <http://dx.doi.org/10.24127/bioedukasi.v12i1.3752>
- Theapparat, Y., Khongthong, S., Rodjan, P., Lertwittayanon, K., & Faroongsarng, D. (2019). Physicochemical properties and in vitro antioxidant activities of pyroligneous acid prepared from brushwood biomass waste of Mangosteen, Durian, Rambutan, and Langsat. *Journal of Forestry Research*, 30, 1139-1148. <https://doi.org/10.1007/s11676-018-0675-9>